Alzamend Neuro (NASDAQ:ALZN) Posts Earnings Results, Misses Expectations By $0.12 EPS

Alzamend Neuro (NASDAQ:ALZN) announced its quarterly earnings results on Thursday. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.12), FiscalAI reports.

Alzamend Neuro Trading Up 1.2%

ALZN stock traded up $0.02 during trading on Thursday, hitting $1.70. The company had a trading volume of 8,710 shares, compared to its average volume of 126,647. The company has a fifty day moving average price of $1.42 and a two-hundred day moving average price of $1.37. The company has a market cap of $8.21 million, a P/E ratio of -0.59 and a beta of 0.23. Alzamend Neuro has a fifty-two week low of $0.84 and a fifty-two week high of $2.68.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Alzamend Neuro from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, August 31st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.00.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Alzamend Neuro stock. DRW Securities LLC grew its stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) by 27.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 116,319 shares of the company’s stock after purchasing an additional 25,074 shares during the quarter. DRW Securities LLC owned about 3.06% of Alzamend Neuro worth $212,000 at the end of the most recent reporting period. 49.61% of the stock is owned by hedge funds and other institutional investors.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.